详文均见于”最近进展”（除非另有说明）; 同一文章可能见于本节内不同分类
Full articles can be found under “Recent Progress” unless specified; same reports may be classified under different categories in this section
乳腺癌 Breast cancer
5/31/2026 2010-2021 年IV期乳腺癌的发病率与生存状况 Incidence and survival of stage IV breast cancer, 2010–2021
5/10/2026 FDA 批准 Vepdegestrant 用于治疗 ER +, HER2-, ESR1 突变的晚期乳腺癌 FDA approves vepdegestrant for ER+, HER2-, ESR1-mutated advanced breast cancer
5/3/2026 因备孕暂停内分泌的 POSITIVE 试验最新进展 Oncologic outcomes maintained after pausing endocrine therapy for pregnancy: POSITIVE trial update
5/2/2026 大麻使用与美国年轻人群中乳腺癌及睾丸癌风险 Cannabis use and increased risk of breast and testicular cancer in young Americans
4/19/2026 奥拉帕利扩展研究：治疗伴有 PALB2 或 BRCA 突变的转移性乳腺癌 Olaparib expansion cohorts: for metastatic breast cancer patients with PALB2 or BRCA mutations: TBCRC 048 rial
3/22/2026 Tucatinib 联合 Trastuzumab 和 Pertuzumab 对比安慰剂作为 HER2 阳性转移性乳腺癌一线维持治疗 Tucatinib versus placebo in combination ith trastuzumab and pertuzumab as first-line maintenance therapy for HER2+ metastatic breast cancer: HER2CLIMB-05
3/1/2026 晚期乳腺癌一线与二线 CDK4/6 抑制剂对总生存期无差别 First-line vs second-line CDK4/6 inhibitor does not impact overall survival in advanced breast cancer: SONIA trial
2/21/2026 术前放疗或可改善乳腺癌的抗肿瘤免疫反应 Preoperative radiation may improve antitumor immune response in breast cancer
2/15/2026 Olaparib monotherapy for metastatic breast cancer with germline mutations in PALB2 or somatic mutations in BRCA1/BRCA2: TBCRC 048 trial
1/4/2026 比较 giredestrant 与标准内分泌疗法作为ER阳性/HER2 阴性早期乳腺癌辅助治疗 Adjuvant therapy using giredestrant vs standard-of-care for ER-positive, HER2-negative early breast cancer: lidERA trial
肺癌 Lung cancer
5/30/2026 Sunvozertinib 作为一线疗法治疗伴 EGFR 外显子 20 插入突变的非小细胞肺癌 First-line Sunvozertinib in NSCLC with EGFR exon 20 insertion mutations
5/17/2026 Zongertinib 作为晚期 HER2 突变非小细胞肺癌的一线治疗 First-line Zongertinib in advanced HER2-mutant non–small-cell lung cancer
2/22/2026 FDA 已批准 amivantamab-vmjw (皮下注射)联合 lazertinib作为一线疗法用于晚期 EGFR突变型非小细胞肺癌 The FDA has approved (subcutaneous) amivantamab-vmjw in combination with lazertinib as a first-line treatment for advanced EGFR-mutant non-small cell lung cancer
2/1/2026 Imneskibart 联合白介素-2在黑色素瘤和非小细胞肺癌中展现抗肿瘤活性 Imneskibart in combination with interleukin-2 demonstrates antitumor activity in melanoma and non-small cell lung cancer
1/25/2026 FDA批准Sevabertinib用于非鳞状非小细胞肺癌 FDA approves Sevabertinib for non-squamous non-small cell lung cancer with HER2 TKD activating mutations
结直肠癌 Colorectal cancer
5/23/2026 表观遗传指纹揭示早发性结直肠癌与农药暴露之间的关联 Epigenetic fingerprints reveal link between early-onset colorectal cancer and pesticide exposure
5/16/2026 Amivantamab 用于化疗难治性 RAS/BRAF 野生型转移性结直肠癌 Amivantamab in chemorefractory RAS/BRAF wild-type metastatic colorectal cancer: OrigAMI-1 trial
4/4/2026 阿替利珠单抗联合 FOLFOX 治疗 III 期错配修复缺陷型结肠癌 Atezolizumab plus FOLFOX for stage III dMMR colon cancer
胃食管癌 Gastro-esophageal cancer
2/7/2026 Zanidatamab 联合化疗±tislelizumab 一线治疗HER2阳性晚期胃食管腺癌 Zanidatamab + chemotherapy ± tislelizumab for first-line HER2-positive locally advanced gastroesophageal adenocarcinoma: HERIZON-GEA-01
1/18/2026 Zanidatamab联合化疗一线治疗HER2阳性不可切除或转移性胃食管腺癌 Zanidatamab + chemotherapy ± for first-line HER2+ unresectable, or metastatic gastroesophageal adenocarcinoma: HERIZON-GEA-01
胰腺癌 Pancreatic cancer
5/9/2026 Daraxonrasib 单药疗法作为转移性胰腺腺癌的一线治疗 Daraxonrasib monotherapy as first-line treatment for metastatic pancreatic adenocarcinoma
4/12/2026 转移性胰腺癌的化疗联合或不联合医学监护生酮饮食的随机II期试验 A randomized phase II trial of chemotherapy with or without a medically supervised ketogenic diet for metastatic pancreatic cancer
3/14/2026 一种诊断治疗晚期胰腺导管腺癌的新型 KRAS G12D 抑制剂 A novel KRAS G12D inhibitor for advanced pancreatic ductal adenocarcinoma
1/31/2026 改进用于早期检测胰腺导管腺癌的血浆标志物 Improving a plasma biomarker panel for early detection of pancreatic ductal adenocarcinoma
1/17/2026 术前mFOLFIRINOX对比PAXG治疗可切除胰腺导管腺癌 Preoperative mFOLFIRINOX versus PAXG for resectable pancreatic ductal adenocarcinoma: PACT-21 CASSANDRA
前列腺癌 Prostate cancer
4/25/2026 一线阿比特龙或/和奥拉帕尼联合奥拉帕尼治疗携带DNA修复缺陷的转移性去势抵抗性前列腺癌 First-line abiraterone or abiraterone plus olaparib in metastatic castration-resistant prostate cancer with DNA repair defects : BRCAAway trial
尿路上皮癌 Urothelial cancer
1/24/2026 首创口服小分子PPARγ抑制剂治疗晚期尿路上皮癌 I 期试验 A phase I trial of first-in-class oral small molecule PPARγ inhibitor for the treatment of advanced urothelial carcinoma
膀胱癌 Bladder cancer
3/8/2026 ctDNA 指导肌层浸润性膀胱癌的疗效适应性膀胱保留治疗 ctDNA to guide response-adapted bladder preservation in muscle invasive bladder cancer: RETAIN trials
肾细胞癌 Renal cell carcinoma
4/11/2026 术后帕博利珠单抗联合belzutifan 用于透明细胞肾细胞癌 Adjuvant pembrolizumab plus belzutifan for clear cell renal cell carcinoma: LITESPARK-022 study
3/15/2026 消融术与手术治疗T1a期肾细胞癌的长期疗效相当 Ablation and surgery for T1a renal cell carcinoma demonstrate comparable long-term outcomes: A Danish Nationwide Registry Study
睾丸癌 Testicular cancer
5/2/2026 大麻使用与美国年轻人群中乳腺癌及睾丸癌风险 Cannabis use and increased risk of breast and testicular cancer in young Americans
卵巢癌 Ovarian cancer
3/28/2026 FDA 批准 Relacorilant 联合纳米炭紫杉醇用于治疗多种铂耐药性妇科肿瘤 Relacorilant with nab-paclitaxel approved for several platinum-resistant gynecologic cancers
2/8/2026 新型 CDK2抑制剂 INCB123667 用于铂类耐药性卵巢癌 A novel CDK2 inhibitor INCB123667 for platinum-resistant ovarian cancer
1/3/2026 Botensilimab 联合巴斯蒂利单抗联合 balstilimab 治疗难治性卵巢癌患者 Botensilimab plus balstilimab for refractory ovarian cancer
宫颈癌 Cervical cancer
3/7/2026 最新进展 Recent Progress–>Cadonilimab 治疗复发性宫颈癌 Bispecific cadonilimab in recurrent cervical cancer
黑色素瘤 Melanoma
4/26/2026 Ruxotemitide 联合帕博利珠单抗治疗难治性转移性黑色素瘤 Ruxotemitide in combination with pembrolizumab treating refractory metastatic melanoma
2/1/2026 Imneskibart 联合白介素-2在黑色素瘤和非小细胞肺癌中展现抗肿瘤活性 Imneskibart in combination with interleukin-2 demonstrates antitumor activity in melanoma and non-small cell lung cancer
脑瘤/ 胶质母细胞瘤 Brain tumor/glioblastoma
2/14/2026 溶瘤病毒激活免疫系统对抗胶质母细胞瘤 Oncolytic viruses activate the immune system to treat glioblastoma
淋巴瘤 Lymphoma
3/29/2026 Odronextamab 联合CHOP 用于初治弥漫大B细胞淋巴瘤 Odronextamab plus CHOP in untreated DLBCL: First results of OLYMPIA-3
多发性骨髓瘤 Myeloma
3/21/2026 首项 I 期试验针对多发性骨髓瘤的体内 CAR T 细胞疗法 First phase I human study of in vivo CAR T in myeloma
肿瘤生物学和治疗/诊断新进展 Tumor biology & New treatment/diagnosis progress
5/24/2026 Rezatapopt（ p53 重激活剂）治疗 TP53 Y220C 突变肿瘤的 I 期研究 Phase 1 study of Rezatapopt, a p53 Reactivator, in TP53 Y220C-mutated tumors
4/18/2026 更新版肿瘤新辅助治疗病理学响应评分指南 Updated pan-tumor guidelines for scoring neoadjuvant pathologic response: by SITC and INMC
4/5/2026 超低剂量免疫疗法治疗难治性实体瘤 Ultra-low-dose immunotherapy in refractory solid tumors: DELII trial
3/21/2026 首项 I 期试验针对多发性骨髓瘤的体内 CAR T 细胞疗法 First phase I human study of in vivo CAR T in myeloma
2/1/2026 Imneskibart 联合白介素-2在黑色素瘤和非小细胞肺癌中展现抗肿瘤活性 Imneskibart in combination with interleukin-2 demonstrates antitumor activity in melanoma and non-small cell lung cancer
流行病学 Epidemiology
5/31/2026 2010-2021 年IV期乳腺癌的发病率与生存状况 Incidence and survival of stage IV breast cancer, 2010–2021
5/23/2026 表观遗传指纹揭示早发性结直肠癌与农药暴露之间的关联 Epigenetic fingerprints reveal link between early-onset colorectal cancer and pesticide exposure
5/2/2026 大麻使用与美国年轻人群中乳腺癌及睾丸癌风险 Cannabis use and increased risk of breast and testicular cancer in young Americans
2/28/2026 微塑料与前列腺癌 Microplastics and prostate cancer
1/11/2026 食品添加剂防腐剂摄入量与癌症发病率 Intake of food additive preservatives and incidence of cancer
1/10/2026 IgG4 相关疾病患者癌症风险增加 Increased cancer risk in patients with IgG4-related disease in South Korea